Stiris Research Inc. announces First Site Initiation on Phase II Frontotemporal Dementia Study

London, ON — January 24, 2018 —

Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announces the first site initiation visit on our Phase II Frontotemporal Dementia study.

“We have initiated our first site on the frontotemporal dementia study and are always grateful for the collaboration with that first site to get the study up and running. We look forward to getting all of the sites open and enrolling in this important study” Amanda Carrera, Vice President.

Frontotemporal dementia is an umbrella term for a group of brain disorders that primarily affect the frontal and temporal lobes of the brain. In frontotemporal dementia, portions of these lobes shrink (atrophy). Signs and symptoms vary, depending on which part of the brain is affected. (,these%20lobes%20shrink%20(atrophy).).


About Stiris Research

Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.

For more information, please contact:

Marketing – Stiris Research Inc.